Navigation Links
HeartWare International, Inc. Temporary Suspension of Trading
Date:9/1/2009

FRAMINGHAM, Mass. and SYDNEY, Sept. 1 /PRNewswire-FirstCall/ -- HeartWare International, Inc. (Nasdaq: HTWR) (ASX: HIN) today confirmed that trading of its CHESS Depositary Interests ("CDIs") on the Australian Securities Exchange ("ASX") was temporarily suspended for the reasons stated below. In consequence, trading of the Company's common stock on NASDAQ is also temporarily suspended. Based on discussions with representatives of NASDAQ and the ASX, the Company believes that trading will recommence on both the ASX and NASDAQ exchanges tomorrow (September 2, 2009).

On August 14, 2009, the Company filed its Quarterly Report on Form 10-Q for the 3 and 6 month period ended June 30, 2009 ("Quarterly Report") with both the ASX and the Securities and Exchange Commission. The Quarterly Report is prepared under U.S. generally accepted accounting principles and otherwise in compliance with the requirements of the Securities Exchange Act of 1934, as amended.

As permitted by ASX Listing Rules, the Company is entitled to file its Quarterly Report with the ASX for the purposes of satisfying Australian financial reporting requirements. However, it is a technical requirement of the ASX Listing Rules now that HeartWare is headquartered in the United States that, in addition to the Company's US reporting obligations, the Company's independent public accountant, Grant Thornton, must provide a brief review to Australian stockholders. In filing its Quarterly Report with the ASX, this supplemental review was omitted from our filing with ASX and, in consequence, the Company's securities on the ASX have been temporarily suspended pending filing of the relevant document (with NASDAQ trading being automatically suspended in consequence). Grant Thornton's review will be completed and file
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. HeartWare Appoints Timothy J. Barberich to Board of Directors
2. U.S. Federal Trade Commission to Challenge Thoratecs Proposed Acquisition of HeartWare International
3. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
4. JPMorgans Principal Investment Management Group to Invest in Chindex International, Inc.
5. Corium International, Inc. Announces Appointment of Phyllis Gardner, M.D. and Daniel G. Welch to Board
6. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
7. Chindex International, Inc. to Present at 2008 UBS Global Healthcare Services Conference
8. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
9. Bio-Clean International, Inc. to Present at Bluechip Capital Investment Forum
10. MINRAD International, Inc. Announces Appointment of David T. DiGiacinto as President and Chief Operating Officer
11. VWR International, LLC Acquires Jencons (Scientific) Ltd, UK
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ) ... Application (CTA) with the United Kingdom,s ... approval to initiate clinical trials for the continued development ... on the Company receiving CTA regulatory approval, the Company ... the safety, tolerability and dose escalation of Anatabine Citrate ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
(Date:12/22/2014)... Dec. 22, 2014 GenomeDx Biosciences today announced ... Cancer Classifier, a genomic test for prostate cancer, was ... men managed by radical prostatectomy without adjuvant therapy. Although ... relatively uncommon, using tumor genomics to identify these men ... is an important advance. The study has been ...
(Date:12/22/2014)... 22, 2014 ITRA Global, one of ... of commercial real estate, has further expanded its global ... Perth and Brisbane, Western Australia, reports Mylinda Vick, CCIM, ... ITRA Global / ACORPP (Australian Corporate Property and ... company providing property services to a wide range of ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime, ... at the 4th Annual Citi Biotech Day in New York ... parties may access a live audio webcast of the conference ... www.BMRN.com . A replay of the call will be ...
... March 25 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX:SDI), ... sepsis, today announced that the 29th International Symposium ... Belgium from March 24-27, 2009 will feature a ... that will include presentations from six thought leaders ...
... SAN DIEGO, March 25 Aethlon Medical, Inc. ... that supports the advancement of the Aethlon Hemopurifier(R) ... cure rates. The Hemopurifier(R) is a first-in-class medical ... infectious disease through real-time therapeutic filtration of infectious ...
Cached Biology Technology:BioMarin to Present at the 4th Annual Citi Biotech Day 2Spectral announces presentations at the 29TH International Symposium on Intensive Care and Emergency Medicine focusing on the role of endotoxin 2Aethlon Medical Announces Data Supported Strategy to Increase Hepatitis-C (HCV) Cure Rates 2Aethlon Medical Announces Data Supported Strategy to Increase Hepatitis-C (HCV) Cure Rates 3Aethlon Medical Announces Data Supported Strategy to Increase Hepatitis-C (HCV) Cure Rates 4Aethlon Medical Announces Data Supported Strategy to Increase Hepatitis-C (HCV) Cure Rates 5
(Date:12/15/2014)... 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a ... recognition system measures the overall facial feature of ... and the distance between eyes. Facial recognition is ...
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
(Date:12/10/2014)... 9, 2014  Valencell, a leader in performance biometric ... staggering demand from its licensees for highly accurate, clinically ... not solely coming from fitness and health sectors, but ... "A wearable is only as useful as the biometric ... ultimate driver in long-term mass consumer adoption of wearable ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... Boulders deposited by an ancient glacier that once covered the ... provided more evidence of the extraordinary power and reach of ... Ocean current system that could happen again and continues to ... has found geochemical clues near the summit of Mauna Kea ...
... August 4, 2010 Researchers at the Hebrew University ... the first time a gene associated with susceptibility to ... a significant step toward better understanding and treating of ... problem, afflicting approximately 20% of adults. Some individuals ...
... PITTSBURGHCarnegie Mellon University,s Yoed Rabin has received three ... of Health (NIH) to develop biothermal technology for ... Cryopreservation is the preservation of tissues and organs ... transplantation and regenerative medicine, whereas cryosurgery is the ...
Cached Biology News:Ancient Hawaiian glaciers reveal clues to global climate impacts 2Ancient Hawaiian glaciers reveal clues to global climate impacts 3Hebrew University researchers identify gene related to chronic pain 2Carnegie Mellon's Yoed Rabin receives grants 2
Request Info...
... service provides the premium quality siRNAs you ... siRNAs can be readily ordered online by ... or by providing the sense and antisense ... Validated and Silencer Pre-designed siRNAs, which are ...
... Ambion's custom siRNA service provides the ... gene silencing research. Custom siRNAs can be ... 19-21 base target sequence, or by providing ... check out Ambion's Silencer Validated and Silencer ...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
Biology Products: